Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Gritstone bio, Inc. GRTS
$2.38
-$0.21 (-8.81%)
На 18:01, 12 мая 2023
+152.10%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
232953632.00000000
-
week52high
5.85
-
week52low
1.71
-
Revenue
9269000
-
P/E TTM
-2
-
Beta
0.53848600
-
EPS
-1.34000000
-
Last Dividend
0.00000000
-
Next Earnings Date
11 мая 2023 г. в 20:00
Описание компании
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate for the treatment of common solid tumors comprising metastatic non-small cell lung cancer, colorectal cancer, pancreatic cancer, and shared neoantigen-positive tumors. In addition, it develops CORAL, a SARS-CoV-2 vaccine platform designed to deliver spike and additional SARS-CoV-2 T cell epitopes for protection and broader immunity against SARS-CoV-2 variants; and a therapeutic vaccine candidate designed to treat and cure human immunodeficiency virus (HIV) infection. It has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Goldman Sachs | Sell | Neutral | 22 авг 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 09 мая 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 14 мар 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 20 янв 2021 г. |
| Baird | Underperform | Outperform | 20 янв 2021 г. |
| Piper Sandler | Overweight | 31 окт 2022 г. | |
| HC Wainwright & Co. | Buy | Buy | 07 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Corey Lawrence | A | 38000 | 38000 | 12 авг 2022 г. |
| Rizvi Naiyer | A | 19000 | 19000 | 17 июн 2022 г. |
| Jones Elaine V | A | 19000 | 19000 | 17 июн 2022 г. |
| Krognes Steve E. | A | 19000 | 19000 | 17 июн 2022 г. |
| Heyman Richard A. | A | 19000 | 19000 | 17 июн 2022 г. |
| Fisher Clare | A | 8693 | 8693 | 17 июн 2022 г. |
| Agarwal Shefali | A | 19000 | 19000 | 17 июн 2022 г. |
| Thompson Rahsaan | A | 115440 | 115440 | 31 янв 2022 г. |
| Thompson Rahsaan | A | 58698 | 19240 | 31 янв 2022 г. |
| Jones Erin | A | 163013 | 163013 | 31 янв 2022 г. |
Новостная лента
Gritstone bio, Inc. (GRTS) Q1 2023 Earnings Call Transcript
Seeking Alpha
11 мая 2023 г. в 22:42
Gritstone bio, Inc. (NASDAQ:GRTS ) Q1 2023 Earnings Conference Call May 11, 2023 4:30 AM ET Company Participants George MacDougall - Director, Investor Relations and Corporate Communications Andrew Allen - Co founder, President and Chief Executive Officer Celia Economides - Executive Vice President and Chief Financial Officer Conference Call Participants Marc Frahm - TD Cowen Ted Tenthoff - Piper Sandler Jonathan Miller - Biotech and Pharmaceuticals Mayank Mamtani - B. Riley Securities Sean Lee - HC Wainwright Operator My name is Erika and welcome to Gritstone bio First Quarter 2023 Earnings Conference Call.
Gritstone bio Inc. (GRTS) Reports Q1 Loss, Lags Revenue Estimates
Zacks Investment Research
11 мая 2023 г. в 19:02
Gritstone bio Inc. (GRTS) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.34 per share a year ago.
Gritstone bio: Q4 2023 Data Readout Is Going To Be Major Inflection Point
Seeking Alpha
23 апр 2023 г. в 04:25
Gritstone bio: Q4 2023 Data Readout Is Going To Be Major Inflection Point.
Gritstone bio Inc. (GRTS) Q4 2022 Results - Earnings Call Transcript
Seeking Alpha
09 мар 2023 г. в 22:21
Gritstone bio Inc. (NASDAQ:GRTS ) Q4 2022 Earnings Conference Call March 9, 2023 4:30 PM ET Company Participants George MacDougall - Director, Investor Relations and Corporate Communications Andrew Allen - Co-Founder, President, CEO and Director Vassiliki Economides - Executive VP and CFO Karin Jooss - Head of Research and Development Conference Call Participants Marc Frahm - TD Cowen Ted Tenthoff - Piper Sandler Mayank Mamtani - B. Riley Securities Arthur He - H.
Gritstone bio Inc. (GRTS) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research
09 мар 2023 г. в 19:49
Gritstone bio Inc. (GRTS) delivered earnings and revenue surprises of 3.23% and 38.38%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?